Metaplastic breast cancer, which was also reported as poorly responsive to neoadjuvant treatment [100], frequently expresses immune checkpoint markers forkhead box P3 (FOXP3) and PD-L1 and may benefit from immune-based therapies [101]. The gene discussed is FOXP3; the disease is breast carcinoma.